Nocturnal Blood Pressure in Young Adults and Cognitive Function in Midlife: The Coronary Artery Risk Development in Young Adults (CARDIA) Study by Yano, Yuichiro et al.
1240 American Journal of Hypertension 28(10) October 2015
Original article
As the population grows older worldwide, the challenge is 
not only to extend limits of lifespan but also to maintain 
normal activities of daily living in the later years of life. 
Cognitive dysfunction or dementia is a critical issue because 
it can cause a cascade of sequela such as falls, loss of inde-
pendence, need for hospital care, and even cardiovascu-
lar- or noncardiovascular-related death.1 Efforts to prevent 
cognitive dysfunction have become a major public health 
goal. To do so, an understanding of the risk factors con-
tributing to cognitive dysfunction, and identification those 
at younger age who may be at risk for developing cognitive 
dysfunction, are becoming top priorities.
The association between higher blood pressure (BP) 
measured in clinic/office and lower cognitive function has 
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BACKGROUND
Nocturnal blood pressure (BP) is associated with risk for cardiovascu-
lar events. However, the relationship between nocturnal BP in young 
adults and cognitive function in midlife remains unclear.
METHODS
We used data from the ambulatory BP monitoring substudy of the 
Coronary Artery Risk Development in Young Adults Study, including 
224 participants (mean age 30 years, 45% men, 63% African Americans). 
At the 20-year follow-up, the Stroop test (executive function), Digit 
Symbol Substitution Test (psychomotor speed), and Rey Auditory 
Verbal Learning Test (verbal memory) were assessed.
RESULTS
Baseline mean office, daytime, and nocturnal BP were 109/73, 120/74, 
and 107/59 mm Hg, respectively. Nocturnal BP dipping, calculated as 
(nocturnal systolic BP [SBP] − daytime SBP) × 100/daytime SBP, was 
divided into quartiles (Q1: −39.3% to −16.9%; Q2: −16.8% to −13.2%, 
Q3 [reference]: −13.1% to −7.8%, and Q4: −7.7% to +56.4%). In multiple 
regression analyses, the least nocturnal SBP dipping (Q4 vs. reference) 
and higher nocturnal diastolic BP level were associated with worse 
Stroop scores, with adjustments for demographic and clinical char-
acteristics, and cumulative exposure to office BP during follow-up (β 
[standard error]: 0.37 [0.18] and 0.19 [0.07], respectively; all P < 0.05). 
Digit Symbol Substitution Test and Rey Auditory Verbal Learning Test 
were not significantly associated with nocturnal SBP dipping or noctur-
nal SBP/diastolic BP levels.
CONCLUSIONS
Among healthy young adults, less nocturnal SBP dipping and higher 
nocturnal diastolic BP levels were associated with lower executive func-
tion in midlife, independent of multiple measures of office BP during 
long-term follow-up.
Keywords: blood pressure; cognitive function; hypertension; midlife; 
nocturnal blood pressure; young adults.
doi:10.1093/ajh/hpv028
Correspondence: Yuichiro Yano (yyano@jichi.jp; yuichiro.yano@
northwestern.edu).
Initially submitted December 18, 2014; date of first revision January 
3, 2015; accepted for publication February 2, 2015; online publication 
March 16, 2015.
© American Journal of Hypertension, Ltd 2015. All rights reserved. 
For Permissions, please email: journals.permissions@oup.com
1Department of Preventive Medicine, Northwestern University 
Feinberg School of Medicine, Chicago, Illinois, USA;  2Department of 
Epidemiology, University of Alabama at Birmingham, Birmingham, 
Alaska, USA;  3Division of Cardiovascular Sciences, National Heart, Lung, 
and Blood Institute, Bethesda, Maryland, USA;  4Vascular Biology and 
Hypertension Program, Division of Cardiovascular Disease, Department 
of Medicine, University of Alabama at Birmingham, Birmingham, 
Alaska, USA;  5Hypertension Research Program and Department of 
Family Medicine, University of North Carolina at Chapel Hill, North 
Carolina, USA;  6Departments of Internal Medicine and Neurology and 
Stroke Program, University of Michigan Health System, Veterans Affairs 
Health Services Research and Development Center of Excellence, Ann 
Arbor, Michigan, USA;  7Division of Epidemiology and Community 
Health, School of Public Health, University of Minnesota, Minneapolis, 
Minnesota, USA;  8Department of Medicine, Center for Behavioral 
Cardiovascular Health, Columbia University, New York, USA. 
October
American Journal of Hypertension 28(10) October 2015 1241
Nocturnal BP and Cognition
been well established.1–3 Additionally, ambulatory BP meas-
ures, in particular nocturnal BP abnormalities (i.e., higher 
absolute values and less nocturnal BP dipping), have been 
reported to be associated with cognitive dysfunction;4–10 
most of these data were obtained in cross-sectional analyses 
for older populations, raising the possibility that comorbidi-
ties (e.g., cerebrovascular diseases with or without symp-
toms) could have affected both participants’ nocturnal BP 
and cognition.11,12 To our knowledge, no studies have exam-
ined whether nocturnal BP measured during young adult-
hood is associated with cognitive function in midlife, and 
the association is independent of long-term office BP values 
during follow-up. The Coronary Artery Risk Development 
in Young Adults (CARDIA) Study provides a unique oppor-
tunity to examine these issues, as CARDIA enrolled only 
young adults (18–30 years) with few comorbidities.
Using CARDIA data, we assessed whether nocturnal BP 
levels and BP dipping in young adults are associated with 
measures of cognitive function 20 year later in midlife, inde-
pendent of long-term office BP values during follow-up.
METHODS
Overall design
The CARDIA Study is a multicenter longitudinal cohort 
of 5,115 young adults initially ages 18–30 years in 1985–1986 
(see Supplementary Data). Black and white adults, who were 
healthy at enrollment, were recruited from 4 US cities and 
underwent baseline examination (Year 0: Y0) and follow-
up examinations at Y2, Y5, Y7, Y10, Y15, Y20, and Y25. The 
CARDIA study and this CARDIA ambulatory blood pres-
sure monitoring (ABPM) substudy were approved by the 
appropriate institutional review boards, and informed con-
sent was obtained from each study participant.
As described previously,13 ABPM was performed in Y5 at 
1 site (Birmingham, AL). A total of 316 people (147 men and 
169 women; 112 whites and 204 blacks), selected randomly 
at the Birmingham center, completed this substudy.
BP and other measurements
The methods in office BP measures are shown in 
Supplementary Data. The baseline BP (Y5) and cumulative 
exposure of BP through Y5 to Y25 (Y5–25; mm Hg × year; the 
formula is shown in Supplementary Figure S1) were used as 
adjustment factors.
At Y5, ABPM was performed over a 24-hour period with a 
Suntech Accutracker II (Suntech Medical, Morrisville, NC),13 
using an appropriately sized cuff inflated approximately 
every 20 minutes during the day (6:00 am–10:00 pm) and 
every 30 minutes during the night (10:00 pm–6:00 am). As 
done in a previous report of CARDIA ABPM,13 we defined 
daytime BP as average BP between 10:00 am and 10:00 pm 
and nocturnal BP between 12:00 am and 6:00 am. The mag-
nitude of nocturnal BP dipping was calculated as (nocturnal 
SBP–daytime SBP) × 100/daytime SBP.14,15 Nocturnal BP 
dipping calculated by SBP is strongly correlated with that 
calculated by diastolic BP (DBP; r = 0.6, P < 0.0001). Most 
of the prior literature used SBP to calculate nocturnal BP 
dipping,14,15 so we did as well. We assessed “poor sleep qual-
ity” during the ABPM session as any report of being unable 
to fall asleep, being awakened ≥5 times, or not being able to 
sleep at all.13
Data on other factors including education, physical activ-
ity, and laboratory values were collected using standardized 
protocols and quality control across study centers and exam-
inations (see Supplementary Data).
Cognitive function assessment
A battery of standardized tests to measure cognitive func-
tion was performed at the Y25 examination.16 Training and 
certification of CARDIA technicians for measurement of 
cognitive function were performed centrally by CARDIA 
investigators and coordinating center data quality assurance 
staff. The Stroop test evaluates the ability to view complex 
visual stimuli and to respond to one stimulus dimension 
while suppressing the response to another dimension, an 
executive skill largely attributed to frontal lobe function.17 
The interference score provides a measure of how much 
additional executive processing is needed to respond to an 
incongruent trial; thus, a higher interference score indi-
cates worse performance on the task. Each trial was scored 
by summing the number of errors and the time required 
to complete each trial. An interference score was calcu-
lated by subtracting the score on the incongruent trial from 
the second congruent trial. The Digit Symbol Substitution 
Test (DSST), a subtest of the Wechsler Adult Intelligence 
Scale (3rd edition), assesses an array of cognitive domains, 
most prominently visual motor speed, sustained attention, 
and working memory. The range of scores is 0–133, with 
increasing scores indicating better performance. The Rey 
Auditory Verbal Learning Test (RAVLT) assesses the ability 
to memorize and to retrieve words (verbal memory) after 
several presentations of the word list immediately one after 
another, and then after a delay of 10 minutes. Results from 
the long-delay (10 minutes) free recall were used in analyses. 
The range of scores is 0–15, with increasing scores indicating 
better performance.
Analysis
Among 316 participants, we excluded 14 participants 
with missing data on daytime BP or nocturnal BP, 60 par-
ticipants who did not attend the follow-up examination at 
Y25, 2 participants with missing data on cognitive function, 
and 16 participants with missing data on covariates. As a 
result, we included 224 participants who attended the Y5, Y7, 
Y10, Y15, Y20, and Y25 examinations and completed ABPM at 
Y5 and cognitive tests at Y25. The included participants had 
a lower proportion of current smoking at Y5 (25.0 vs. 38.0 
%; P  =  0.02) compared with those not included (n  =  92), 
but the mean age (30.2 vs. 29.6 years), gender distribution 
(55.4% vs. 48.9% women), racial distribution (63.4 vs. 67.4% 
African American), mean educational attainment (14.1 vs. 
13.8 years), and mean office SBP/DBP levels at Y5 (108.7/73.1 
vs. 110.3/73.1 mm Hg; all P ≥ 0.24) were similar between the 
two groups. Compared with those in the entire CARDIA 
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cohort (n  =  4,891), the included participants were more 
likely to be African American (63.4% vs. 51.0%) but showed 
no differences in age, sex, or office BP levels (Supplementary 
Table S1).
Statistical analyses were performed using SAS software 
version 9.3 (SAS Institute Inc, Cary, NC). Demographic 
and clinical characteristics of the participants across quar-
tiles were tested by analysis of variance or chi-squared test. 
Unadjusted and multivariable-adjusted linear regression 
models were used to assess the association of nocturnal BP 
with cognitive function measures. Because there is no stand-
ard definition on physiological nocturnal BP dipping in 
young adults, we defined Quartile 3, centered on −10% noc-
turnal BP dipping, as the reference group. This approach was 
used in a previous report of CARDIA ABPM substudy to 
test the association of nocturnal BP with coronary calcium.13 
Our analyses were performed with sequential adjustment. In 
the first step, we carried out unadjusted analyses (Model 1). 
In the second step, we adjusted for demographic covariates 
including age (Y5), sex, race (black and white), and educa-
tional attainment in years (Model 2). In the last step, we fur-
ther adjusted for the clinical characteristics at Y25 (i.e., body 
mass index, smoking, alcohol, physical activity, glucose and 
lipid parameters, use of antihypertensive drugs, and inci-
dence of stroke) plus office BP at Y5 (Model 3), daytime BP 
at Y5 (Model 4), or cumulative exposure of office BP (Y5–25; 
Model 5). Statistical significance was defined by a P value of 
<0.05 on 2-sided tests.
RESULTS
Of the 224 participants, 45% were men, 63% were African 
American, their mean age was 30 years, and 0.5% were treated 
with antihypertensive drugs at baseline. Table 1 provides the 
demographic and clinical characteristics of the included 
participants stratified by the quartile of nocturnal SBP dip-
ping. By definition, Quartile 1 showed the most nocturnal 
SBP dipping (−39.3% to −16.9%), and Quartile 4 (−7.7% to 
+56.4%) showed the least. The mean time of BP measures 
was 46 ± 10 times in daytime and 14 ± 2 times in nighttime. 
Across quartiles, age, sex, and educational attainment were 
similar. The proportion of African Americans was higher in 
the higher quartiles of nocturnal BP dipping. Supplementary 
Tables S2–S6 show the associations between nocturnal BP 
Table 1. Clinical characteristics of the included participants according to quartiles of nocturnal SBP dipping (n = 224) 
Quartile: magnitude of nocturnal SBP dipping
Total (n = 224)
Q1: −39.3% to 
−16.9% (n = 56)
Q2: −16.8% to 
−13.2% (n = 56)
Q3: −13.1% to −7.8% 
(n = 56)
Q4: −7.7% to 
+56.4% (n = 56) P values
Demographic variables at Y5 (baseline)
 Age at Y5, years 30.2 ± 3.8 30.8 ± 3.9 29.6 ± 3.8 30.3 ± 3.8 30.3 ± 3.5 0.40
 Men, % 44.6 41.1 50.0 35.7 51.8 0.27
 Blacks, % 63.4 44.6 53.6 73.2 82.1 <0.0001
 Education, years 14.1 ± 2.1 13.7 ± 2.0 14.4 ± 2.1 14.5 ± 2.4 13.7 ± 2.0 0.07
 Poor sleep quality 
during ABPM, %
16.7 13.0 14.8 13.0 25.9 0.21
Clinical characteristics at Y25 (follow-up)
 Body mass index, 
kg/m2
31.9 ± 6.9 30.4 ± 6.5 32.1 ± 6.4 32.4 ± 7.6 32.9 ± 6.9 0.24
 Current smoker, % 17.9 17.9 8.9 16.1 28.6 0.06
 Current drinkers, % 41.5 35.7 42.9 42.9 44.6 0.78
 Physical activity, 
exercise units
250.2 ± 230.7 268.1 ± 256.9 283.5 ± 237.7 223.4 ± 202.9 225.6 ± 222.0 0.41
 Antihypertensive 
medication, %
45.1 39.3 42.9 50.0 48.2 0.65
 Incident stroke, % 0.9 0 0 3.6 0 0.11
 Fasting glucose, 
mg/dl
99.6 ± 31.5 96.7 ± 30.6 96.9 ± 20.1 98.2 ± 24.9 106.7 ± 44.5 0.28
 Total cholesterol, 
mg/dl
182.5 ± 34.6 184.2 ± 36.5 178.0 ± 39.8 183.3 ± 30.4 184.6 ± 31.5 0.72
 High-density 
lipoprotein, mg/dl
54.7 ± 16.1 57.5 ± 19.2 52.0 ± 16.7 56.1 ± 13.1 53.1 ± 14.5 0.23
Abbreviations: ABPM, ambulatory blood pressure monitoring; Q, quartile; SBP, systolic blood pressure.
Data are expressed as the means ± standard deviation or percentage. P values were obtained by analysis of variance or chi-squared test 
among quartile groups. The magnitude of nocturnal SBP dipping was calculated as (nocturnal SBP–daytime SBP) × 100/daytime SBP. Poor 
sleep quality was defined as any report of being unable to fall asleep, being awakened ≥5 times, or not being able to sleep at all during the ABPM 
session. Statistical significance was defined as P < 0.05.
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and clinical characteristics. Men, blacks, and higher body 
mass index were associated with higher nocturnal BP. No 
difference was observed in nocturnal BP between those with 
or without poor sleep quality. Office and ambulatory BP val-
ues across quartiles are shown in Table 2. Cumulative expo-
sure of office SBP and DBP during follow-up was higher in 
Quartiles 2–4 vs. 1 of nocturnal dipping, but the trend was 
not statistically significant (P = 0.08).
Among participants, mean ± standard deviation scores on 
the Stroop test, DSST, and RAVLT were 25.9 ± 11.6 seconds + 
errors (range = −21.0 to 92.0: higher score indicates worse 
function), 65.1 ± 15.7 symbols (range = 8.0 to 114.0: lower 
score indicates worse function), 8.7 ± 3.2 words (range = 0 
to 15.0: lower score indicates worse function), respectively. 
Figure 1 shows mean scores of cognitive function test across 
quartiles of nocturnal dipping. Participants in Quartile 4 had 
the worst Stroop test scores, and worst DSST and RAVLT 
scores, whereas those in Quartile 3 showed the best Stroop 
and DSST scores.
Table 3 shows unadjusted and multivariable-adjusted lin-
ear regression models examining the associations of noc-
turnal BP with cognitive function. Quartile 4 (vs. Quartile 
3)  was associated with worse Stroop and DSST scores 
(Model 1 in Table 3). Nocturnal SBP dipping, when assessed 
as a continuous variable, was not associated with cognitive 
function. Higher nocturnal DBP was associated with worse 
Stroop test scores, and worse DSST and RAVLT scores 
(Model 1 in Table 3). Adjustments for the demographic vari-
ables attenuated the associations (Model 2), but Quartile 4 
(vs. Quartile 3)  and higher nocturnal DBP remained sig-
nificantly associated with worse Stroop test scores, with 
adjustments also for clinical characteristics, and office BP 
at Y5 (Model 3), daytime BP at Y5 (Model 4), or cumulative 
exposure of office BP (Y5–25; Model 5). In contrast, when the 
relationship of office or daytime BP to cognitive function 
was examined, office BP at Y5, daytime SBP or DBP at Y5, 
and cumulative exposure of office SBP or DBP (Y5–25) were 
not associated with the Stroop test, DSST, and RAVLT scores 
(Models 3–5 in Table 3; all P ≥ 0.09). When we adjusted for 
the presence of poor sleep quality during ABPM as covari-
ates, the overall findings were similar (Supplementary Table 
S7). When we used clinical characteristics at Y5 instead of 
those at Y25 as adjusted factors, the results were mostly simi-
lar (Supplementary Table S8).
There were no significant interactions between race and 
any of the nocturnal BP variables (nocturnal SBP dipping, 
nocturnal SBP levels, or nocturnal DBP levels) in associa-
tions with the Stroop test, DSST, and RAVLT scores (all P 
≥ 0.15).
DISCUSSION
Among healthy young adults (mean age 30  years and 
mean office BP 109/73 mm Hg), we show that nocturnal SBP 
dipping less than 7.7% (compared with that between 13.1% 
and 7.8%) and higher nocturnal DBP levels were associated 
with lower executive function (i.e., Stroop test) 20 years later 
in midlife. The associations were independent of multiple 
measures of office BP during long-term follow-up.
The finding in this study of a stronger association of noc-
turnal BP than office or daytime BP with cognitive function 
raises questions about mechanisms. Some plausible, albeit 
speculative, explanations are suggested. First, cerebrovascular 
responsiveness is reduced during sleep, and cerebral blood 
flow decreases by approximately 30% at least during nonrapid 
eye movement stages.18,19 The neurovascular unit may be 
Table 2. BP parameters according to quartiles of nocturnal SBP dipping (n = 224)
Quartile: magnitude of nocturnal SBP dipping
Total (n = 224)
Q1: −39.3% to 
−16.9% (n = 56)
Q2: −16.8% to 
−13.2% (n = 56)
Q3: −13.1% to 
−7.8% (n = 56)
Q4: −7.7% to 
+56.4% (n = 56) P values
BP at Y5 (baseline)
 Office SBP, mm Hg 108.7 ± 9.8 105.1 ± 9.0 110.3 ± 10.0 111.2 ± 9.9 108.1 ± 9.3 0.004
 Office DBP, mm Hg 73.1 ± 9.1 69.9 ± 8.8 74.8 ± 9.1 74.9 ± 8.2 73.0 ± 9.7 0.01
 Daytime SBP, mm Hg 120.4 ± 11.0 121.2 ± 9.1 122.3 ± 12.0 119.5 ± 11.8 118.6 ± 10.9 0.28
 Daytime DBP, mm Hg 73.5 ± 7.4 74.6 ± 6.1 74.4 ± 8.3 73.0 ± 8.0 71.9 ± 6.9 0.18
 Nocturnal SBP, mm Hg 106.5 ± 14.8 95.9 ± 7.3 104.0 ± 10.1 106.7 ± 11.2 119.5 ± 17.8 <0.0001
 Nocturnal DBP, mm Hg 59.3 ± 9.3 54.5 ± 5.3 58.5 ± 7.0 59.9 ± 7.6 64.2 ± 12.8 <0.0001
BP at Y25 (follow-up)
 Office SBP, mm Hg 122.7 ± 18.0 120.2 ± 15.7 122.9 ± 19.6 124.0 ± 18.0 123.7 ± 18.6 0.67
 Office DBP, mm Hg 75.3 ± 10.9 73.3 ± 9.3 75.0 ± 11.5 76.2 ± 11.3 76.7 ± 11.4 0.36
Cumulative exposure of office BP through Y5–Y25
 Cumulative exposure of office SBP, 
mm Hg × year
2285.6 ± 241.6 2227.2 ± 214.0 2290.4 ± 229.5 2336.3 ± 244.4 2288.3 ± 268.9 0.12
 Cumulative exposure of office 
DBP, mm Hg × year
1488.2 ± 156.3 1441.8 ± 149.2 1499.8 ± 151.6 1512.0 ± 162.4 1499.2 ± 156.3 0.08
Abbreviations: BP, blood pressure; DBP, diastolic blood pressure; Q, quartile; SBP, systolic blood pressure.
Data are expressed as the means ± standard deviation. P values were obtained by analysis of variance.
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particularly vulnerable to BP burden during sleep.20 Second, 
in terms of physical and mental activity as well as body posi-
tion, the nocturnal BP compared with office or daytime BP 
is better standardized without being influenced by environ-
mental stimuli.14,15 Third, nocturnal BP compared with office 
or daytime BP could reflect concurrent pathophysiology, such 
as sympathovagal imbalance, volume retention, impaired 
salt excretion, and disturbed breathing during sleep.21–25 
Obstructive sleep apnea in particular could affect both noc-
turnal BP increase and cognitive dysfunction via noctur-
nal hypoxia and resultant sympathetic nerve activation.24,25 
Nocturnal BP dipping is further affected by sporadic factors, 
such as physical activity during daytime and orthostatic BP 
changes.14,15 From our data, whether less nocturnal SBP dip-
ping and higher nocturnal DBP in young adults are simply 
markers of concurrent pathophysiology or related in a causal 
pathway to pathogenesis in cognitive dysfunction remains 
uncertain and promotes us to further explore whether improv-
ing nocturnal BP abnormalities in young adults can prevent 
lower cognitive function in those middle-aged or over.
We found that nocturnal SBP was not associated with 
cognitive function after multivariable adjustment. The rela-
tive importance of DBP and SBP to cardiovascular disease 
risk differs with aging; DBP is more predictive for cardiovas-
cular disease events than SBP in younger adults.26 Among 
adolescents ages 7–20  years, higher 24-hour DBP rather 
than 24-hour SBP, even within the normotensive range, was 
associated with impaired cerebrovascular reactivity.27 Our 
findings may complement the data, by showing a prospec-
tive association of higher nocturnal DBP in young adult-
hood with lower cognitive function in midlife.
Nocturnal SBP dipping and nocturnal DBP level were 
associated with Stroop score, a test reflecting white matter 
integrity in the frontal lobe,17,28 but not with RAVLT and 
DSST scores. Our sample size was small, so the null associa-
tions of the RAVLT and DSST tests might be a consequence 
of lack of power. However, the associations of higher BP with 
white matter disease have been shown to be greater for the 
frontal lobe than other areas.2,20,29 The exact mechanism of 
the regional specificity remains unclear, but the type and size 
of vessels, myogenic reactivity, vasodilator capacity, neuro-
vascular units, and innervation of the cerebral blood ves-
sels may vary by brain location.3,20 Different components of 
ambulatory BP are known to affect different parts of cerebral 
structure and function.4,8,10 Among older individuals, higher 
nocturnal SBP and less nocturnal SBP dipping were specifi-
cally associated with frontal lobe atrophy and subsequently 
lower executive function.8,10 Further investigations using 
brain magnetic resonance imaging may allow us to under-
stand the underlying pathways (e.g., vascular dysfunction, 
brain atrophy, or impaired brain integrity) between higher 
nocturnal BP and cognitive dysfunction, and whether brain 
regional specificity exists in relation to nocturnal BP.
In our study, 82% of those with the least nocturnal BP 
dipping (i.e., Quartile 4)  were African Americans. African 
Americans are known to have higher nocturnal BP and less 
dipping compared with whites.30–32 The mechanisms remain 
uncertain, but salt sensitivity, abnormal autonomic func-
tion, socioeconomic factors, and psychological factors have 
each been associated with altered diurnal BP variation14,15 
and are more common in African Americans compared 
with whites.21,30,32–36 Our sample size was not large enough 
to allow robust race-specific analyses, but we observed no 
significant interactions between race and any of the noctur-
nal BP variables in association with cognitive function.
The major strengths of this study include long-term, 
repeated examinations of well-characterized participants 
from young adulthood to middle age and application of a 
comprehensive standardized cognitive test battery. However, 
there are limitations. First, we could not assess changes in 
cognitive function from baseline to follow-up, and we can-
not conclude whether the low cognitive function scores 
reflect cognitive decline. Further CARDIA examinations 
including cognitive function would enable us to explore the 
time course of cognitive function in participants with abnor-
mal nocturnal BP. Second, although our findings were sta-
tistically significant, whether nocturnal BP measurement in 
young adults, particularly in those who had normal office BP 
with minimum cardiovascular risks, is clinically meaning-
ful remains uncertain. Further investigations are warranted, 
including analyses of the cost-effectiveness, availability, and 
invasiveness (e.g., with respect to sleep disturbances, dis-
comfort, and restrictions in daily activities) of ABPM, as 
well as analyses identifying clinical characteristics (e.g., risk 
factors) in which ABPM is recommended. Third, we have 
Figure 1.   Cognitive function score according to the quartile of noc-
turnal SBP dipping. Mean (95% confidence intervals) of each cognitive 
function score according to the quartile of nocturnal SBP dipping are 
shown. Q1 indicates Quartile 1, and the magnitude of nocturnal BP dip-
ping is as follows; Q1, −39.3% to −16.9% (n = 56); Q2, −16.8 to −13.2% 
(n = 56); Q3, −13.1% to −7.8% (n = 56); Q4, −7.7% to +56.4% (n = 56). P 
values were obtained by analysis of variance, and statistical significance 
was defined as P < 0.05. Abbreviations: BP, blood pressure; SBP, systolic 
blood pressure. 
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only a single measurement of ABPM, and the reproducibility 
was limited. Some participants might have had sleep depri-
vation during the overnight BP monitoring. We adjusted for 
sleep quality and the results were similar. Also, it can be dif-
ficult to discern the transition from daytime to nocturnal BP 
measurements (i.e., bedtime), though several studies simi-
larly used fixed clock-time intervals.14,15 Fourth, a number of 
participants from the original cohort were excluded, so there 
is a potential selection bias. Fifth, we did not assess what 
classes of antihypertensive drug were used in this study, and 
some of these drugs can affect cognitive function.37 Finally, 
our sample consists of black and white adults, so our find-
ings cannot be generalized to other race/ethnic groups.
Among healthy young adults, less nocturnal SBP dipping 
and higher nocturnal DBP were associated with lower exec-
utive function 20 years later in midlife. Our results may help 
to identify young adults at risk for developing lower cogni-
tive function in midlife. Replications in different studies/
Table 3. Associations of nocturnal BP in young adults with cognitive function in midlife: Unadjusted and multivariable-adjusted linear 
regression models (n = 224) 
Model 1 (unadjusted) Model 2 Model 3 Model 4 Model 5
β (SE) R2, % β (SE) R2, % β (SE) R2, % β (SE) R2, % β (SE) R2, %
Stroop test (seconds + errors)
 Nocturnal SBP dipping
  Q1 0.06 (0.19) 3.6 0.11 (0.18) 12.5 0.15 (0.19) 17.9 NA NA 0.12 (0.18) 17.8
  Q2 0.20 (0.19) 0.26 (0.18) 0.24 (0.18) NA 0.24 (0.18)
  Q3 (reference) Ref Ref Ref NA Ref
  Q4 0.57 (0.19)** 0.41 (0.18)* 0.38 (0.18)* NA 0.37 (0.18)*
 Nocturnal SBP dipping, % 0.12 (0.07) 1.1 0.07 (0.06) 11.2 0.05 (0.06) 17.1 NA NA 0.05 (0.07) 17.1
 Nocturnal SBP, mm Hg 0.16 (0.07)* 2.0 0.07 (0.07) 11.5 0.04 (0.07) 17.0 0.06 (.08) 16.5 0.04 (0.07) 17.0
 Nocturnal DBP, mm Hg 0.30 (0.06)*** 8.6 0.22 (0.06) *** 15.7 0.20 (0.07)** 20.2 0.21 (0.08)* 20.1 0.19 (0.07)** 20.6
DSST (symbols)
 Nocturnal SBP dipping
  Q1 −0.18 (0.19) 2.0 −0.18 (0.18) 17.9 −0.16 (0.19) 18.6 NA NA −0.21 (0.18) 19.7
  Q2 −0.13 (0.19) −0.15 (0.18) −0.16 (0.18) NA −0.16 (0.18)
  Q3 (reference) Ref Ref Ref NA Ref
  Q4 −0.49 (0.19)** −0.26 (0.18) −0.25 (0.18) NA −0.31 (0.18)
 Nocturnal SBP dipping, % −0.06 (0.07) 0.4 −0.01 (0.06) 17.8 −0.002 (0.06) 18.6 NA NA −0.01 (0.06) 19.3
 Nocturnal SBP, mm Hg −0.12 (0.07) 1.1 −0.01 (0.07) 17.8 0.001 (0.07) 18.6 0.01 (0.08) 18.5 0.03 (0.07) 19.4
 Nocturnal DBP, mm Hg −0.15 (0.07)* 1.9 −0.05 (0.06) 18.0 −0.03 (0.08) 18.7 0.003 (0.08) 18.6 −0.005 (0.07) 18.7
RAVLT (words)
 Nocturnal SBP dipping
  Q1 0.34 (0.19) 2.0 0.29 (0.18) 14.3 0.30 (0.19) 15.1 NA NA 0.29 (0.19) 15.1
  Q2 −0.01 (0.19) 0.002 (0.18) 0.01 (0.18) NA 0.01 (0.18)
  Q3 (reference) Ref Ref Ref NA Ref
  Q4 −0.16 (0.19) 0.05 (0.18) 0.05 (0.19) NA 0.05 (0.19)
 Nocturnal SBP dipping, % −0.17 (0.07)* 2.4 −0.11 (0.06) 14.8 −0.11 (0.07) 15.7 NA NA −0.11 (0.07) 15.8
 Nocturnal SBP, mm Hg −0.20 (0.07)** 3.6 −0.07 (0.07) 14.2 −0.07 (0.07) 14.9 −0.12 (0.08) 15.8 −0.07 (0.07) 15.0
 Nocturnal DBP, mm Hg −0.22 (0.07)** 4.3 −0.12 (0.06) 15.2 −0.10 (0.08) 15.7 −0.18 (0.08)* 16.2 −0.14 (0.07) 15.7
Abbreviations: BP, blood pressure; DBP, diastolic blood pressure; DSST, Digit Symbol Substitution Test; NA, not applicable; Q, quartile; 
RAVLT, Rey Auditory Verbal Learning Test; SBP, systolic blood pressure; SE, standard error.
Bold values suggest significant associations. β means standardized regression coefficient, and R2 means a measure for the model predic-
tion. Quartile of nocturnal SBP dipping consists of Q1 (−39.3% to −16.9%), Q2 (−16.8% to −13.2%), Q3 (−13.1% to −7.8%), and Q4 (−7.7% to 
+56.4%). A higher score of the Stroop test indicates worse performance on the task, and a lower score of DSST and RAVLT indicates worse 
performance on the task. As adjusted factors, each model includes some covariates as follows: Model 2 includes demographic variables (age 
at baseline, sex, race, and education); Model 3 includes demographic variables + clinical characteristics at Y25 (body mass index, smoking, 
drinking, physical activity, fasting glucose, total cholesterol/high-density lipoprotein, use of antihypertensive drugs, incidence of stroke) + office 
BP at Y5; Model 4 includes demographic variables + clinical characteristics at Y25 + daytime BP at Y5; Model 5 included demographic variables 
+ clinical characteristics at Y25 + cumulative exposure of office BP (Y5–25); statistical significance was defined as P < 0.05. *P < 0.05; **P < 0.01; 
***P < 0.001.
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cohorts with larger samples size are warranted. Continued 
follow-up in CARDIA may allow us to discern the associa-
tion of nocturnal BP in young adulthood with aging-related 
cognitive decline and dementia through older age. Such evi-
dence may help to direct potential strategies for preventing 
lower cognitive function in those middle-aged or over.
SUPPLEMENTARY MATERIAL
Supplementary materials are available at American 
Journal of Hypertension (http://ajh.oxfordjournals.org).
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